{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:18:14Z","timestamp":1789690694132,"version":"4.0.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01570-y","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:14:20Z","timestamp":1780938860000},"page":"827-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications"],"prefix":"10.1007","volume":"46","author":[{"given":"Mohammadsalman","family":"Parsapour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-0537","authenticated-orcid":false,"given":"Navid","family":"Omidkhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-1781","authenticated-orcid":false,"given":"Omid","family":"Arasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"1570_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transd Target Ther. 2023;8(1):262.","journal-title":"Signal Transd Target Ther."},{"issue":"15","key":"1570_CR2","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/cancers16152754","volume":"16","author":"AM Eshaq","year":"2024","unstructured":"Eshaq AM, Flanagan TW, Hassan SY, et al. Non-receptor tyrosine kinases: their structure and mechanistic role in tumor progression and resistance. Cancers. 2024;16(15):2754.","journal-title":"Cancers"},{"key":"1570_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100103","author":"X Du","year":"2021","unstructured":"Du X, Yang B, An Q, et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation. 2021. https:\/\/doi.org\/10.1016\/j.xinn.2021.100103.","journal-title":"Innovation"},{"key":"1570_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824","volume":"130","author":"C Corvaja","year":"2024","unstructured":"Corvaja C, Passaro A, Attili I, et al. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development. Cancer Treat Rev. 2024;130:102824.","journal-title":"Cancer Treat Rev"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon J, Steuer C, Ramalingam S, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29:i20\u20137.","journal-title":"Ann Oncol"},{"issue":"6","key":"1570_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304782","volume":"19","author":"SJ Bakri","year":"2024","unstructured":"Bakri SJ, Lynch J, Howard-Sparks M, et al. Vorolanib, sunitinib, and axitinib: a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. PLoS ONE. 2024;19(6):e0304782.","journal-title":"PLoS ONE"},{"issue":"1","key":"1570_CR7","doi-asserted-by":"publisher","first-page":"vdab133","DOI":"10.1093\/noajnl\/vdab133","volume":"3","author":"A Qin","year":"2021","unstructured":"Qin A, Musket A, Musich PR, et al. Receptor tyrosine kinases as druggable targets in glioblastoma: do signaling pathways matter? Neuro Oncol Adv. 2021;3(1):vdab133.","journal-title":"Neuro Oncol Adv."},{"issue":"3","key":"1570_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/1078-0432.CCR-12-2353","volume":"19","author":"NG Chau","year":"2013","unstructured":"Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013;19(3):524\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1570_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10120-024-01478-6","volume":"27","author":"J Liu","year":"2024","unstructured":"Liu J, Zhu T, Zhao R, et al. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer. Gastric Cancer. 2024;27(3):495.","journal-title":"Gastric Cancer"},{"key":"1570_CR10","doi-asserted-by":"publisher","first-page":"1089066","DOI":"10.3389\/fphar.2022.1089066","volume":"13","author":"DD Singh","year":"2022","unstructured":"Singh DD, Lee H-J, Yadav DK. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Front Pharmacol. 2022;13:1089066.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1570_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian A, Lee P, Taylor J, et al. Preclinical sctivity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1570_CR12","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220\u20137.","journal-title":"Clin Cancer Res"},{"key":"1570_CR13","doi-asserted-by":"publisher","first-page":"175628482110169","DOI":"10.1177\/17562848211016959","volume":"14","author":"A Granito","year":"2021","unstructured":"Granito A, Forgione A, Marinelli S, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Ther Adv Gastroenterol. 2021;14:17562848211016960.","journal-title":"Ther Adv Gastroenterol"},{"issue":"16","key":"1570_CR14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Pexidartinib: first approval. Drugs. 2019;79(16):1805\u201312.","journal-title":"Drugs"},{"issue":"1","key":"1570_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-022-02298-1","volume":"41","author":"T Yang","year":"2022","unstructured":"Yang T, Sim K-Y, Ko G-H, et al. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-\u03baB signaling activation. J Exp Clin Cancer Res. 2022;41(1):82.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1570_CR16","doi-asserted-by":"publisher","first-page":"e2120165","DOI":"10.1001\/jamanetworkopen.2021.20165","volume":"4","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang X, Wang Z, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(7):e2120165.","journal-title":"JAMA Netw Open"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784\u2013803.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1570_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/1744666X.2016.1214576","volume":"12","author":"S Kubo","year":"2016","unstructured":"Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016;12(9):911\u20139.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"1570_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092668","volume":"19","author":"S Del Bino","year":"2018","unstructured":"Del Bino S, Duval C, Bernerd F. Clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact. Int J Mol Sci. 2018;19(9):2668.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1570_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0190-9622(79)70018-1","volume":"1","author":"KH Kaidbey","year":"1979","unstructured":"Kaidbey KH, Agin PP, Sayre RM, et al. Photoprotection by melanin: a comparison of black and Caucasian skin. J Am Acad Dermatol. 1979;1(3):249\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1570_CR21","doi-asserted-by":"crossref","unstructured":"Brar G, Dhaliwal A, Brar AS, et al. A comprehensive review of the role of UV radiation in photoaging processes between different types of skin. Cureus. 2025;17(3):e81109.","DOI":"10.7759\/cureus.81109"},{"issue":"4","key":"1570_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/pcmr.13171","volume":"37","author":"P Xu","year":"2024","unstructured":"Xu P, Yang L, Lai S, et al. Effects of EGFR\u2010TKI on epidermal melanin unit integrity: therapeutic implications for hypopigmented skin disorders. Pigment Cell Melanoma Res. 2024;37(4):514\u201329.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"1570_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040521","volume":"17","author":"M Karkoszka","year":"2024","unstructured":"Karkoszka M, Rok J, Wrze\u015bniok D. Melanin biopolymers in pharmacology and medicine: skin pigmentation disorders, implications for drug action, adverse effects and therapy. Pharmaceuticals Basel. 2024;17(4):521.","journal-title":"Pharmaceuticals Basel"},{"issue":"10","key":"1570_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the Global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"key":"1570_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1874372202115010023","volume":"15","author":"GI Alhetheli","year":"2021","unstructured":"Alhetheli GI. The impact of vitiligo on patients\u2019 psychological status and sexual function: cross-sectional questionnaire-based study. Open Dermatol J. 2021;15:23\u201330.","journal-title":"Open Dermatol J"},{"issue":"7","key":"1570_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.36849\/JDD.8519","volume":"24","author":"JY Wang","year":"2025","unstructured":"Wang JY, Kabakova M, Philip R, et al. The impact of hyperpigmentation on the lives of patients. J Drugs Dermatol. 2025;24(7):668\u201374.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1570_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1473-2165.2008.00384.x","volume":"7","author":"A Taylor","year":"2008","unstructured":"Taylor A, Pawaskar M, Taylor SL, et al. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol. 2008;7(3):164\u20138.","journal-title":"J Cosmet Dermatol"},{"key":"1570_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071144","author":"SA D'Mello","year":"2016","unstructured":"D\u2019Mello SA, Finlay GJ, Baguley BC, et al. Signaling pathways in melanogenesis. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17071144.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1570_CR29","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5021\/ad.2014.26.4.532","volume":"26","author":"HS Song","year":"2014","unstructured":"Song HS, Kang HY. Imatinib mesylate-induced hyperpigmentation of the nose and palate. Ann Dermatol. 2014;26(4):532\u20133.","journal-title":"Ann Dermatol"},{"key":"1570_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/817094","volume":"1","author":"U Romeo","year":"2015","unstructured":"Romeo U, Palaia G, Fantozzi PJ, et al. A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia. Case Rep Dentistry. 2015;1:817094.","journal-title":"Case Rep Dentistry."},{"issue":"1","key":"1570_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40902-017-0136-y","volume":"39","author":"GP Bombeccari","year":"2017","unstructured":"Bombeccari GP, Garagiola U, Pallotti F, et al. Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking Imatinib. Maxillofac Plast Reconstr Surg. 2017;39(1):37.","journal-title":"Maxillofac Plast Reconstr Surg"},{"issue":"5","key":"1570_CR32","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","volume":"111","author":"U Mattsson","year":"2011","unstructured":"Mattsson U, Halbritter S, Serikoff EM, et al. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2011;111(5):e12-16.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol."},{"key":"1570_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-209335","volume":"2015","author":"A Lyne","year":"2015","unstructured":"Lyne A, Creedon A, Bailey BMW. Mucosal pigmentation of the hard palate in a patient taking imatinib. BMJ Case Rep. 2015;2015:bcr2015209335.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"1570_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2230.2011.04196.x","volume":"37","author":"J Steele","year":"2012","unstructured":"Steele J, Triantafyllou A, Rajlawat B, et al. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. Clin Exp Dermatol. 2012;37(4):432\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"1570_CR35","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/ijd.13931","volume":"57","author":"F Di Tullio","year":"2018","unstructured":"Di Tullio F, Mandel VD, Scotti R, et al. Imatinib\u2010induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature. Int J Dermatol. 2018;57(7):784\u201390.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1570_CR36","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.jcms.2011.07.010","volume":"40","author":"RG Resende","year":"2012","unstructured":"Resende RG, Teixeira RGL, de Oliveira Vasconcelos f, et al. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg. 2012;40(5):e140\u20133.","journal-title":"J Craniomaxillofac Surg"},{"key":"1570_CR37","doi-asserted-by":"crossref","unstructured":"Wong M, Sade S, Gilbert M, et al. Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J. 2011;17(5):4","DOI":"10.5070\/D3498194BX"},{"issue":"2","key":"1570_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","volume":"6","author":"C-C Li","year":"2012","unstructured":"Li C-C, Malik SM, Blaeser BF, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol. 2012;6(2):290\u20135.","journal-title":"Head Neck Pathol"},{"issue":"6","key":"1570_CR39","first-page":"95","volume":"116","author":"N Lueken","year":"2019","unstructured":"Lueken N, Kaune KM, Zutt M. A large gray\u2013blue macule on the hard palate as an adverse effect of imatinib. Deutsches \u00c4rzteblatt Int. 2019;116(6):95.","journal-title":"Deutsches \u00c4rzteblatt Int"},{"issue":"5","key":"1570_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.23589","volume":"89","author":"LE Roeker","year":"2014","unstructured":"Roeker LE, Wolanskyj AP. Imatinib\u2010associated melanosis of the palate. Am J Hematol. 2014;89(5):564.","journal-title":"Am J Hematol"},{"issue":"1","key":"1570_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3109\/10428194.2012.702904","volume":"54","author":"T-L Khoo","year":"2013","unstructured":"Khoo T-L, Catalano A, Supple S, et al. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma. 2013;54(1):186\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1570_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0378-6323.19727","volume":"72","author":"K Prabhash","year":"2006","unstructured":"Prabhash K, Biswas G, Prasad N, et al. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2006;72:63.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1570_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02706.x","author":"T Mcpherson","year":"2009","unstructured":"Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02706.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1570_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/0019-5154.164447","volume":"60","author":"P Balasubramanian","year":"2015","unstructured":"Balasubramanian P, Jagadeesan S, Thomas J. Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia. Indian J Dermatol. 2015;60(5):523.","journal-title":"Indian J Dermatol"},{"key":"1570_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/0378-6323.182387","volume":"82","author":"S Ghunawat","year":"2016","unstructured":"Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma-like pigmentation: report of five cases and review of literature. Indian J Dermatol Venereol Leprol. 2016;82:409.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"1570_CR46","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/1078155220903364","volume":"26","author":"H Rehman","year":"2020","unstructured":"Rehman H, Hakim N, Sugarman R, et al. Hyperpigmentation due to imatinib: a rare case of cutaneous involvement. J Oncol Pharm Pract. 2020;26(6):1511\u20135.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"1570_CR47","first-page":"686","volume":"47","author":"P Agrawal","year":"2015","unstructured":"Agrawal P, Singh O, Nigam AK, et al. Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female. Indian J Pharmacol. 2015;47(6):686\u2013785.","journal-title":"Indian J Pharmacol"},{"issue":"3","key":"1570_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MPH.0b013e318033a76c","volume":"29","author":"N Singh","year":"2007","unstructured":"Singh N, Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29(3):208\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1570_CR49","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","volume":"22","author":"T Yang","year":"2004","unstructured":"Yang T, Chen K, Yin M, et al. Paronychia and skin hiperpigmentation induced by gefitinib in advanced nonsamm-cell lung cancer. J Clin Oncol. 2004;22:4646\u20138.","journal-title":"J Clin Oncol"},{"key":"1570_CR50","doi-asserted-by":"crossref","unstructured":"Chuenwipasakul D, Wititsuwannakul J, Asawanonda P, Rerknimitr P. Gefifitinib-associated lichen planus pigmentosus-like eruption. Dermatol Online J. 2021;27(5).","DOI":"10.5070\/D327553616"},{"issue":"1","key":"1570_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000503758","volume":"6","author":"T Cosio","year":"2020","unstructured":"Cosio T, Mazzilli S, Bianchi L, et al. The dark side of gefitinib: reflectance confocal microscopy applied to hair hyperpigmentation. Skin Append Disord. 2020;6(1):44\u20137.","journal-title":"Skin Append Disord."},{"issue":"9","key":"1570_CR52","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/1759-7714.14383","volume":"13","author":"K Funai","year":"2022","unstructured":"Funai K. Rare ashy dermatosis\u2010like hyperpigmentation associated with osimertinib. Thorac Cancer. 2022;13(9):1436\u20137.","journal-title":"Thorac Cancer"},{"key":"1570_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2017.1355316","author":"H Zhu","year":"2018","unstructured":"Zhu H, Zhu Z, Huang W, et al. Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer. Cutan Ocul Toxicol. 2018. https:\/\/doi.org\/10.1080\/15569527.2017.1355316.","journal-title":"Cutan Ocul Toxicol"},{"issue":"32","key":"1570_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043778","volume":"104","author":"N Yang","year":"2025","unstructured":"Yang N, Cao J. Safety evaluation of tucatinib: adverse event signal mining and analysis based on the FAERS database. Medicine (Baltimore). 2025;104(32):e43778.","journal-title":"Medicine (Baltimore)"},{"issue":"02","key":"1570_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/2231-0770.154199","volume":"5","author":"M Gupta","year":"2015","unstructured":"Gupta M, Gupta H, Gupta A. Sorafenib induced acral pigmentation: a new entity. Avicenna J Med. 2015;5(02):46\u20138.","journal-title":"Avicenna J Med"},{"key":"1570_CR56","doi-asserted-by":"crossref","unstructured":"Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J. 2013;19(5):18184.","DOI":"10.5070\/D3195018184"},{"issue":"12","key":"1570_CR57","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/2013.jamadermatol.192","volume":"148","author":"D Giacchero","year":"2012","unstructured":"Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418\u201320.","journal-title":"Arch Dermatol"},{"issue":"8","key":"1570_CR58","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archdermatol.2009.177","volume":"145","author":"HH Kong","year":"2009","unstructured":"Kong HH, Fine HA, Stern JB, et al. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol. 2009;145(8):923\u20135.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1570_CR59","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/archdermatol.2011.30","volume":"147","author":"S Brooks","year":"2011","unstructured":"Brooks S, Linehan WM, Srinivasan R, et al. Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol. 2011;147(3):364\u20135.","journal-title":"Arch Dermatol"},{"key":"1570_CR60","doi-asserted-by":"crossref","unstructured":"Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14(7):7.","DOI":"10.5070\/D3472203P2"},{"issue":"3","key":"1570_CR61","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1468-3083.2006.01981.x","volume":"21","author":"V Brazzelli","year":"2007","unstructured":"Brazzelli V, Prestinari F, Barbagallo T, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol. 2007;21(3):384\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1570_CR62","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/cncr.20267","volume":"100","author":"KW Leong","year":"2004","unstructured":"Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004;100(11):2486\u20137.","journal-title":"Cancer"},{"issue":"2","key":"1570_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1067\/mjd.2003.44","volume":"48","author":"L Valeyrie","year":"2003","unstructured":"Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2):201\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1570_CR64","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1002\/cncr.11812","volume":"98","author":"AS Tsao","year":"2003","unstructured":"Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98(11):2483\u20137.","journal-title":"Cancer"},{"issue":"3","key":"1570_CR65","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1200\/JCO.2002.20.3.869","volume":"20","author":"P Raanani","year":"2002","unstructured":"Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology: case 3. Depigmentation in a chronic myeloid leukemia patient treated eith STI-571. J Clin Oncol. 2002;20(3):869\u201370.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1570_CR66","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1046\/j.1365-2141.2003.04151_4.x","volume":"120","author":"A Drummond","year":"2003","unstructured":"Drummond A, Micallef-Eynaud P, Douglas W, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol. 2003;120(5):911\u20133.","journal-title":"Br J Haematol"},{"issue":"1","key":"1570_CR67","first-page":"2","volume":"42","author":"AH Reksodiputro","year":"2010","unstructured":"Reksodiputro AH, Syafei S, Prayogo N, et al. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital. Acta Med Indones. 2010;42(1):2\u20135.","journal-title":"Acta Med Indones"},{"issue":"2","key":"1570_CR68","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10689-017-0024-8","volume":"17","author":"S Farag","year":"2018","unstructured":"Farag S, Van der Kolk L, van Boven H, et al. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview. Fam Cancer. 2018;17(2):247\u201353.","journal-title":"Fam Cancer"},{"issue":"1","key":"1570_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/pde.13040","volume":"34","author":"T Piqueres-Zubiaurre","year":"2017","unstructured":"Piqueres-Zubiaurre T, Martinez de Lagran Z, Gonz\u00e1lez-P\u00e9rez R, et al. Familial progressive hyperpigmentation, cutaneous mastocytosis, and gastrointestinal stromal tumor as clinical manifestations of mutations in the c-KIT receptor gene. Pediatr Dermatol. 2017;34(1):84\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"1570_CR70","first-page":"9","volume":"44","author":"SA \u00c1vila","year":"2014","unstructured":"\u00c1vila SA, Pe\u00f1aloza J, Gonz\u00e1lez F, et al. Dysphagia, melanosis, gastrointestinal stromal tumors and a germinal mutation of the KIT gene in an Argentine family. Acta Gastroenterol Latin. 2014;44(1):9\u201315.","journal-title":"Acta Gastroenterol Latin"},{"issue":"11","key":"1570_CR71","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/archdermatol.2009.263","volume":"145","author":"T Campbell","year":"2009","unstructured":"Campbell T, Felsten L, Moore J. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol. 2009;145(11):1313\u20136.","journal-title":"Arch Dermatol"},{"issue":"5","key":"1570_CR72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/cup.12298","volume":"41","author":"M Llamas-Velasco","year":"2014","unstructured":"Llamas-Velasco M, Fraga J, Kutzner H, et al. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol. 2014;41(5):417\u201326.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"1570_CR73","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1684\/ejd.2015.2684","volume":"26","author":"E Dervis","year":"2016","unstructured":"Dervis E, Ayer M, Akin Belli A, et al. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: a six-year follow up. Eur J Dermatol. 2016;26(2):133\u20137.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"1570_CR74","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.leukres.2008.12.023","volume":"33","author":"C Cerchione","year":"2009","unstructured":"Cerchione C, Fabbricini R, Pane F, et al. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leuk Res. 2009;33(8):e104\u20135.","journal-title":"Leuk Res"},{"issue":"1","key":"1570_CR75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0781.2011.00621.x","volume":"28","author":"V Brazzelli","year":"2012","unstructured":"Brazzelli V, Muzio F, Manna G, et al. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. Photodermatol Photoimmunol Photomed. 2012;28(1):2\u20135.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"1570_CR76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/1346-8138.12342","volume":"41","author":"SK Yun","year":"2014","unstructured":"Yun SK, Song KH, Hwang SR, et al. Hair graying and loss induced by imatinib mesylate. J Dermatol. 2014;41(1):107\u20138.","journal-title":"J Dermatol"},{"issue":"4","key":"1570_CR77","first-page":"395","volume":"8","author":"A Sun","year":"2009","unstructured":"Sun A, Akin RS, Cobos E, et al. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl\/Src family tyrosine kinase inhibitor. J Drugs Dermatol. 2009;8(4):395\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1570_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2340\/00015555-1289","volume":"92","author":"V Brazzelli","year":"2012","unstructured":"Brazzelli V, Grasso V, Barbaccia V, et al. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Dermatol Venereol. 2012;92(2):218\u20139.","journal-title":"Acta Dermatol Venereol."},{"issue":"1","key":"1570_CR79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1346-8138.13150","volume":"43","author":"A Fujimi","year":"2016","unstructured":"Fujimi A, Ibata S, Kanisawa Y, et al. Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia. J Dermatol. 2016;43(1):106\u20137.","journal-title":"J Dermatol"},{"issue":"2","key":"1570_CR80","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4274\/tjh.galenos.2023.2023.0280","volume":"41","author":"V Sharma","year":"2024","unstructured":"Sharma V, Bagrodia V. Hypopigmentation of the skin and hair associated with dasatinib therapy. Turk J Hematol. 2024;41(2):116\u20137.","journal-title":"Turk J Hematol."},{"issue":"11","key":"1570_CR81","volume":"8","author":"K Boudadi","year":"2014","unstructured":"Boudadi K, Chugh R. Diffuse hypopigmentation followed by hyperpigmentation in an African American woman with hemangiopericytoma treated with dasatinib. J Clin Diagn Res. 2014;8(11):QD01.","journal-title":"J Clin Diagn Res"},{"issue":"1","key":"1570_CR82","first-page":"9359086","volume":"2017","author":"KC Webb","year":"2017","unstructured":"Webb KC, Harasimowicz M, Janeczek M, et al. Development of asymmetric facial depigmentation in a patient treated with dasatinib with new-onset hypovitaminosis D: case report and review of the literature. Case Rep Dermatol Med. 2017;2017(1):9359086.","journal-title":"Case Rep Dermatol Med."},{"issue":"1","key":"1570_CR83","first-page":"4062431","volume":"2018","author":"B Alharbi","year":"2018","unstructured":"Alharbi B, Alamri S, Mahdi A, et al. Dasatinib-induced hypopigmentation in pediatric patient with chronic myeloid leukemia: a case report and review of the literature. Case Rep Dermatol Med. 2018;2018(1):4062431.","journal-title":"Case Rep Dermatol Med."},{"issue":"2","key":"1570_CR84","first-page":"163","volume":"42","author":"\u00d6 Ayd\u0131n","year":"2025","unstructured":"Ayd\u0131n \u00d6, Turgut M. Hair re-pigmentation after nilotinib. Turk J Hematol. 2025;42(2):163\u20134.","journal-title":"Turk J Hematol."},{"issue":"6","key":"1570_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-265445","volume":"18","author":"A Dhiman","year":"2025","unstructured":"Dhiman A, Daroach M, Dhiman P. Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 2025;18(6):e265445.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"1570_CR86","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.33312","volume":"127","author":"H Gelderblom","year":"2021","unstructured":"Gelderblom H, Wagner AJ, Tap WD, et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021;127(6):884\u201393.","journal-title":"Cancer"},{"key":"1570_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30764-0","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/s0140-6736(19)30764-0.","journal-title":"Lancet"},{"issue":"5","key":"1570_CR88","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med"},{"key":"1570_CR89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OTT.S345878","volume":"15","author":"A Vaynrub","year":"2022","unstructured":"Vaynrub A, Healey JH, Tap W, et al. Pexidartinib in the management of advanced tenosynovial giant cell tumor: focus on patient selection and special considerations. Onco Targets Ther. 2022;15:53\u201366.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"1570_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100679","volume":"6","author":"M Hamid","year":"2021","unstructured":"Hamid M, Heilbrun LK, Maier J, et al. A Phase 1 study combining pexidartinib, radiation therapy, and androgen deprivation therapy in men with intermediate-and high-risk prostate cancer. Adv Radiat Oncol. 2021;6(4):100679.","journal-title":"Adv Radiat Oncol"},{"key":"1570_CR91","unstructured":"Limbu AL, Xie J, Song JQ. Unexpected extensive hair whitening following baricitinib treatment for alopecia universalis: a case report and mechanistic insights. Cureus. 2024;16(12):e76287."},{"issue":"1","key":"1570_CR92","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1586\/14737140.2015.985660","volume":"15","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther. 2015;15(1):129\u201341.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"1570_CR93","first-page":"557","volume":"16","author":"SE Rosenbaum","year":"2008","unstructured":"Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557\u201366.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1570_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-007-0498-4","volume":"61","author":"CD Britten","year":"2008","unstructured":"Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61(3):515\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"1570_CR95","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s11255-016-1380-2","volume":"48","author":"MH Mir","year":"2016","unstructured":"Mir MH, Changal KH, Aziz SA, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? Int Urol Nephrol. 2016;48(11):1811\u20136.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"1570_CR96","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jaad.2008.12.030","volume":"61","author":"MM Al Enazi","year":"2009","unstructured":"Al Enazi MM, Kadry R, Mitwali H. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. J Am Acad Dermatol. 2009;61(5):905\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1570_CR97","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","volume":"144","author":"JT Hartmann","year":"2008","unstructured":"Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008;144(11):1525\u20136.","journal-title":"Arch Dermatol"},{"issue":"17","key":"1570_CR98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm1309906","volume":"370","author":"C Brzezniak","year":"2014","unstructured":"Brzezniak C, Szabo E. Images in clinical medicine: sunitinib-associated hair depigmentation. N Engl J Med. 2014;370(17):e27.","journal-title":"N Engl J Med"},{"issue":"6","key":"1570_CR99","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000366227","volume":"87","author":"CN Sternberg","year":"2014","unstructured":"Sternberg CN, Davis ID, Deen KC, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology. 2014;87(6):342\u201350.","journal-title":"Oncology"},{"issue":"3","key":"1570_CR100","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-012-9885-8","volume":"31","author":"MJ de Jonge","year":"2013","unstructured":"de Jonge MJ, Hamberg P, Verweij J, et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs. 2013;31(3):751\u20139.","journal-title":"Invest New Drugs"},{"issue":"21","key":"1570_CR101","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1158\/1078-0432.CCR-11-0793","volume":"17","author":"T Yau","year":"2011","unstructured":"Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17(21):6914\u201323.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1570_CR102","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.1158\/1078-0432.CCR-11-1734","volume":"17","author":"M Nieto","year":"2011","unstructured":"Nieto M, Borregaard J, Ersb\u00f8ll J, et al. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin Cancer Res. 2011;17(21):6608\u201314.","journal-title":"Clin Cancer Res"},{"issue":"15_Suppl.","key":"1570_CR103","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.5021","volume":"27","author":"CN Sternberg","year":"2009","unstructured":"Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2009;27(15_Suppl.):5021.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1570_CR104","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2217\/fon.09.112","volume":"5","author":"CA Castaneda","year":"2009","unstructured":"Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol. 2009;5(9):1335\u201348.","journal-title":"Future Oncol"},{"key":"1570_CR105","doi-asserted-by":"crossref","unstructured":"Li J, Li Z, Su T. A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall dermatitis. Ren Fail. 2023;45(1):2213778.","DOI":"10.1080\/0886022X.2023.2213778"},{"key":"1570_CR106","doi-asserted-by":"crossref","unstructured":"\u0160eparovi\u0107 R, Pavlovi\u0107 M, Silovski T, Te\u010di\u0107 Vuger A. Rapid hair depigmentation in patient treated with pazopanib. BMJ Case Rep. 2018;2018:bcr2018224209.","DOI":"10.1136\/bcr-2018-224209"},{"issue":"04","key":"1570_CR107","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4103\/ijmpo.ijmpo_104_17","volume":"39","author":"BJ Srinivasa","year":"2018","unstructured":"Srinivasa BJ, Lalkota BP, Chindar PS, et al. Reversible hypopigmentation with pazopanib. Indian J Med Paediatr Oncol. 2018;39(04):519\u201320.","journal-title":"Indian J Med Paediatr Oncol."},{"issue":"5","key":"1570_CR108","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.medcli.2021.05.017","volume":"158","author":"M Meri-Abad","year":"2022","unstructured":"Meri-Abad M, Blasco Cordellat A, Camps Herrero C. Capillary and cutaneous hypopigmentation secondary to pazopanib. Med Clin (Barc). 2022;158(5):246\u20137.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"1570_CR109","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/0974-7796.204178","volume":"9","author":"FX Inn","year":"2017","unstructured":"Inn FX, Ahmed N, Hing EY, et al. One year survivor of metastatic renal cell carcinoma treated with pazopanib. Urol Ann. 2017;9(2):194\u20136.","journal-title":"Urol Ann"},{"issue":"19","key":"1570_CR110","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1200\/JCO.2009.26.4432","volume":"28","author":"K Sideras","year":"2010","unstructured":"Sideras K, Menefee ME, Burton JK, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol. 2010;28(19):e312\u20133.","journal-title":"J Clin Oncol"},{"key":"1570_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2025.114630","volume":"285","author":"B Castaldo","year":"2025","unstructured":"Castaldo B, Zago A, Ramazzotti S, et al. Pazopanib-induced zebra hair depigmentation. J Pediatr. 2025;285:114630.","journal-title":"J Pediatr"},{"issue":"6","key":"1570_CR112","doi-asserted-by":"publisher","first-page":"791","DOI":"10.5021\/ad.2015.27.6.791","volume":"27","author":"HJ Yun","year":"2015","unstructured":"Yun HJ, Seo YJ, Lee HJ. Gray hair associated with the multitargeted receptor tyrosine kinase inhibitor pazopanib. Ann Dermatol. 2015;27(6):791\u20132.","journal-title":"Ann Dermatol"},{"issue":"11","key":"1570_CR113","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/1346-8138.12654","volume":"41","author":"E Kobayashi","year":"2014","unstructured":"Kobayashi E, Koyama T, Kobayashi K, et al. Reversible hair depigmentation in a Japanese female treated with pazopanib. J Dermatol. 2014;41(11):1021\u20132.","journal-title":"J Dermatol"},{"issue":"6","key":"1570_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13140","volume":"32","author":"M Vaccaro","year":"2019","unstructured":"Vaccaro M, Riso G, Altavilla D, et al. Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma. Dermatol Ther. 2019;32(6):e13140.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1570_CR115","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1684\/ejd.2014.2462","volume":"25","author":"V Sibaud","year":"2015","unstructured":"Sibaud V, Munsch C, Lamant L. Eruptive nevi and hair depigmentation related to regorafenib. Eur J Dermatol. 2015;25(1):85\u20136.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1570_CR116","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","volume":"151","author":"RC Zuo","year":"2015","unstructured":"Zuo RC, Apolo SB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151(2):170\u20137.","journal-title":"JAMA Dermatol"},{"key":"1570_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-13-29","volume":"13","author":"SZ Hussain","year":"2013","unstructured":"Hussain SZ, Asghar A, Ikram M, et al. Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with sorafenib. BMC Endocr Disord. 2013;13:29.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"1570_CR118","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","volume":"2","author":"A Aleem","year":"2009","unstructured":"Aleem A. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2009;2(2):358\u201361.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"1570_CR119","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1111\/1346-8138.15321","volume":"47","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Shimizu A, Ieta K, et al. Generalized lentigines associated with familial gastrointestinal stromal tumors dramatically improved by imatinib treatment. J Dermatol. 2020;47(6):e241\u20132.","journal-title":"J Dermatol"},{"issue":"1","key":"1570_CR120","doi-asserted-by":"publisher","first-page":"35","DOI":"10.37757\/MR2011V13.N1.9","volume":"13","author":"V Pav\u00f3n","year":"2011","unstructured":"Pav\u00f3n V, G\u00f3mez R, Jaime JC, et al. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba. MEDICC Rev. 2011;13(1):35\u201340.","journal-title":"MEDICC Rev"},{"issue":"8","key":"1570_CR121","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1080\/09546634.2017.1328099","volume":"28","author":"WL Kok","year":"2017","unstructured":"Kok WL, Chen Q, Lee SSJ, et al. A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis. J Dermatolog Treat. 2017;28(8):762\u20133.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1570_CR122","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.clinthera.2012.01.014","volume":"34","author":"AM Pick","year":"2012","unstructured":"Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther. 2012;34(3):511\u201320.","journal-title":"Clin Ther"},{"issue":"5","key":"1570_CR123","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"W Lee","year":"2009","unstructured":"Lee W, Lee J, Chang S, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1570_CR124","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/ijd.13852","volume":"57","author":"K Vinay","year":"2018","unstructured":"Vinay K, Yanamandra U, Dogra S, et al. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. Int J Dermatol. 2018;57(3):332\u20138.","journal-title":"Int J Dermatol"},{"key":"1570_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238131","author":"SK Padhy","year":"2021","unstructured":"Padhy SK, Kaliki S. Incidental finding of regressed solitary unilateral choroidal metastasis from lung adenocarcinoma with EGFR exon-19 deletion treated with erlotinib. BMJ Case Rep. 2021. https:\/\/doi.org\/10.1136\/bcr-2020-238131.","journal-title":"BMJ Case Rep"},{"issue":"10","key":"1570_CR126","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","volume":"11","author":"KC Bible","year":"2010","unstructured":"Bible KC, Suman NJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962\u201372.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1570_CR127","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/2047-783X-16-11-491","volume":"16","author":"S Akanay-Diesel","year":"2011","unstructured":"Akanay-Diesel S, Hoff NP, K\u00fcrle S, et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res. 2011;16(11):491\u20134.","journal-title":"Eur J Med Res"},{"issue":"2","key":"1570_CR128","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s11096-012-9615-5","volume":"34","author":"C Vignand-Courtin","year":"2012","unstructured":"Vignand-Courtin C, Martin C, Le Beller C, et al. Cutaneous side effects associated with sunitinib: an analysis of 8 cases. Int J Clin Pharm. 2012;34(2):286\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"1570_CR129","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","volume":"111","author":"JM Grichnik","year":"1998","unstructured":"Grichnik JM, Burch JA, Burchette J, et al. The SCF\/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998;111(2):233\u20138.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1570_CR130","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1046\/j.1523-1747.1999.00643.x","volume":"113","author":"BJ Longley","year":"1999","unstructured":"Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol. 1999;113(1):139\u201340.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1570_CR131","first-page":"683","volume":"22","author":"E Sheikh","year":"2022","unstructured":"Sheikh E, Tran T, Vranic S, et al. Role and significance of c-KIT receptor tyrosine kinase in cancer: a review. Bosnian J Basic Med Sci. 2022;22(5):683.","journal-title":"Bosnian J Basic Med Sci."},{"issue":"1","key":"1570_CR132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","volume":"123","author":"A Galanis","year":"2014","unstructured":"Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94\u2013100.","journal-title":"Blood"},{"issue":"3","key":"1570_CR133","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","volume":"100","author":"A Galanis","year":"2015","unstructured":"Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2015;100(3):e77\u20139.","journal-title":"Haematologica"},{"issue":"3","key":"1570_CR134","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","volume":"16","author":"B Wehrle-Haller","year":"2003","unstructured":"Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 2003;16(3):287\u201396.","journal-title":"Pigment Cell Res"},{"issue":"2","key":"1570_CR135","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdh068","volume":"15","author":"B Arora","year":"2004","unstructured":"Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15(2):358\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"1570_CR136","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00280-009-1070-1","volume":"65","author":"G Fountzilas","year":"2010","unstructured":"Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and\/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010;65(4):649\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1570_CR137","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2133.2006.07359.x","volume":"155","author":"M Cario\u2010Andre","year":"2006","unstructured":"Cario\u2010Andre M, Ardilouze L, Pain C, et al. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006;155(2):493\u20134.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1570_CR138","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00008390-200508000-00008","volume":"15","author":"JB Alexis","year":"2005","unstructured":"Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 2005;15(4):283\u20135.","journal-title":"Melanoma Res"},{"issue":"23","key":"1570_CR139","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1570_CR140","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamadermatol.2013.75","volume":"149","author":"S Samimi","year":"2013","unstructured":"Samimi S, Chu E, Seykora J, et al. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol. 2013;149(5):637\u20139.","journal-title":"JAMA Dermatol"},{"key":"1570_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1324892","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S, Li C, Tu Z, et al. Off-label use of baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K\/Akt\/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells. Front Pharmacol. 2024;15:1324892.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1570_CR142","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/jid.2012.331","volume":"133","author":"H Choi","year":"2013","unstructured":"Choi H, Choi H, Han J, et al. IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2\u2013STAT6 signaling pathway. J Invest Dermatol. 2013;133(2):528\u201336.","journal-title":"J Invest Dermatol"},{"issue":"14","key":"1570_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145137","volume":"21","author":"JE Kim","year":"2020","unstructured":"Kim JE, Lee YJ, Park HR, et al. The effect of JAK inhibitor on the survival, anagen re-entry, and hair follicle immune privilege restoration in human dermal papilla cells. Int J Mol Sci. 2020;21(14):5137.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1570_CR144","first-page":"24","volume":"100","author":"DM Lewis","year":"2009","unstructured":"Lewis DM. Diffuse pigmentation of the palate. J Okla Dent Assoc. 2009;100(8):24\u20135.","journal-title":"J Okla Dent Assoc"},{"issue":"5","key":"1570_CR145","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.otorri.2012.02.004","volume":"63","author":"B Vera-Sirera","year":"2012","unstructured":"Vera-Sirera B, Risue\u00f1o-Mata P, Ricart-Vay\u00e1 JM, et al. Clinicopathological and immunohistochemical study of oral amalgam pigmentation. Acta Otorrinolaringol. 2012;63(5):376\u201381.","journal-title":"Acta Otorrinolaringol"},{"issue":"5","key":"1570_CR146","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1600-0722.2006.00388.x","volume":"114","author":"E Gagari","year":"2006","unstructured":"Gagari E, Rand MK, Tayari L, et al. Expression of stem cell factor and its receptor, c-kit, in human oral mesenchymal cells. Eur J Oral Sci. 2006;114(5):409\u201315.","journal-title":"Eur J Oral Sci"},{"issue":"5","key":"1570_CR147","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","volume":"83","author":"LB Nanney","year":"1984","unstructured":"Nanney LB, Magid M, Stoscheck CM, et al. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol. 1984;83(5):385\u201393.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"1570_CR148","first-page":"505","volume":"10","author":"M Jost","year":"2000","unstructured":"Jost M, Kari C, Rodeck U. The EGF receptor: an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10(7):505\u201310.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1570_CR149","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147(3):598\u2013601.","journal-title":"Br J Dermatol"},{"issue":"21","key":"1570_CR150","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","volume":"14","author":"R Murillas","year":"1995","unstructured":"Murillas R, Larcher F, Conti C, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 1995;14(21):5216\u201323.","journal-title":"EMBO J"},{"issue":"3","key":"1570_CR151","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1096\/fj.00-0368com","volume":"15","author":"NV Botchkareva","year":"2001","unstructured":"Botchkareva NV, Khelgatian M, Longley Jack B, et al. SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J. 2001;15(3):645\u201358.","journal-title":"FASEB J"},{"issue":"1","key":"1570_CR152","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbrc.2016.03.064","volume":"473","author":"I Kobayashi","year":"2016","unstructured":"Kobayashi I, Takahashi F, Nurwidya F, et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. Biochem Biophys Res Commun. 2016;473(1):125\u201332.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1570_CR153","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160425","volume":"11","author":"L Zhou","year":"2016","unstructured":"Zhou L, Xu M, Yang Y, et al. Activation of \u03b2-catenin signaling in CD133-positive dermal papilla cells drives postnatal hair growth. PLoS ONE. 2016;11(7):e0160425.","journal-title":"PLoS ONE"},{"issue":"1","key":"1570_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07691-z","volume":"9","author":"MD Morgan","year":"2018","unstructured":"Morgan MD, Pairo-Castineira E, Rawlik K, et al. Genome-wide study of hair colour in UK Biobank explains most of the SNP heritability. Nat Commun. 2018;9(1):5271.","journal-title":"Nat Commun"},{"issue":"2","key":"1570_CR155","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jid.2021.06.018","volume":"142","author":"S Guida","year":"2022","unstructured":"Guida S, Guida G, Goding CR. MC1R functions, expression, and implications for targeted therapy. J Invest Dermatol. 2022;142(2):293-302.e1.","journal-title":"J Invest Dermatol"},{"issue":"19","key":"1570_CR156","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375\u201383.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1570_CR157","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","volume":"24","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"1570_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03049-w","volume":"5","author":"C Estrada","year":"2022","unstructured":"Estrada C, Mirabal-Ortega L, M\u00e9ry L, et al. MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells. Commun Biol. 2022;5(1):101.","journal-title":"Commun Biol"},{"issue":"11","key":"1570_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166583","volume":"11","author":"A Tse","year":"2016","unstructured":"Tse A, Verkhivker G. Exploring molecular mechanisms of paradoxical activation in the BRAF kinase dimers: atomistic simulations of conformational dynamics and modeling of allosteric communication networks and signaling pathways. PLoS ONE. 2016;11(11):e0166583.","journal-title":"PLoS ONE"},{"issue":"4","key":"1570_CR160","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","volume":"2","author":"O Dereure","year":"2001","unstructured":"Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253\u201362.","journal-title":"Am J Clin Dermatol"},{"key":"1570_CR161","doi-asserted-by":"crossref","unstructured":"Dasanu CA, Dutcher, Alexandrescu DT. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100(3):328\u201331.","DOI":"10.1097\/SMJ.0b013e31802f01a9"},{"issue":"8","key":"1570_CR162","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1111\/ijd.13257","volume":"55","author":"P Espinosa Lara","year":"2016","unstructured":"Espinosa Lara P, Bueno C, Aranegui B, et al. Yellowish nail pigmentation caused by sunitinib. Int J Dermatol. 2016;55(8):e462\u20133.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1570_CR163","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1523-1747.2000.00095.x","volume":"115","author":"M Oka","year":"2000","unstructured":"Oka M, Nagai H, Ando H, et al. Regulation of melanogenesis through phosphatidylinositol 3-kinase-Akt pathway in human G361 melanoma cells. J Invest Dermatol. 2000;115(4):699\u2013703.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1570_CR164","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/0974-7753.51923","volume":"1","author":"RM Tr\u00fceb","year":"2009","unstructured":"Tr\u00fceb RM. Oxidative stress in ageing of hair. Int J Trichol. 2009;1(1):6\u201314.","journal-title":"Int J Trichol"},{"issue":"4","key":"1570_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093589","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Luo L-F, Liu X-M, et al. Premature graying as a consequence of compromised antioxidant activity in hair bulb melanocytes and their precursors. PLoS ONE. 2014;9(4):e93589.","journal-title":"PLoS ONE"},{"key":"1570_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1415846","volume":"15","author":"F Lazzara","year":"2024","unstructured":"Lazzara F, Conti F, Sasmal PK, et al. Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy. Front Pharmacol. 2024;15:1415846.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1570_CR167","first-page":"1062","volume":"10","author":"Y Balagula","year":"2011","unstructured":"Balagula Y, Pulitzer MP, Maki RG, et al. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol. 2011;10(9):1062\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1570_CR168","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-230X-11-116","volume":"2","author":"H Liu","year":"2011","unstructured":"Liu H, Liao G, Yan Z. Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event. BMC Gastroenterol. 2011;2(11):116.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"1570_CR169","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.0307-6938.2001.00947.x","volume":"27","author":"B Kumar","year":"2002","unstructured":"Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermato. 2002;27(1):8\u201313.","journal-title":"Clin Exp Dermato"},{"issue":"4","key":"1570_CR170","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/exd.14260","volume":"30","author":"JM Yardman\u2010Frank","year":"2021","unstructured":"Yardman\u2010Frank JM, Fisher DE. Skin pigmentation and its control: from ultraviolet radiation to stem cells. Exp Dermatol. 2021;30(4):560\u201371.","journal-title":"Exp Dermatol"},{"issue":"Suppl. 1","key":"1570_CR171","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl. 1):31\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"1570_CR172","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/jdv.18200","volume":"36","author":"V Sibaud","year":"2022","unstructured":"Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol. 2022;36:51\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1570_CR173","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14428","volume":"33","author":"M Llamas\u2010Velasco","year":"2020","unstructured":"Llamas\u2010Velasco M, Ovejero\u2010Merino E, Garc\u00eda\u2010Diez A, et al. Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: general description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment\u2019s prognostic factor. Dermatol Ther. 2020;33(6):e14428.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1570_CR174","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179\u201396.","journal-title":"J Am Acad Dermatol"},{"key":"1570_CR175","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","volume":"95","author":"J Cury-Martins","year":"2020","unstructured":"Cury-Martins J, Eris APM, Abdalla CMZ, et al. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. 2020;95:221\u201337.","journal-title":"An Bras Dermatol"},{"key":"1570_CR176","unstructured":"Hassan S, Zhou XA. Drug-induced pigmentation. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"12","key":"1570_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13123044","volume":"13","author":"M Marino","year":"2025","unstructured":"Marino M, Rosset F, Nervo A, et al. Cutaneous adverse events of tyrosine kinase inhibitors in endocrine tumors: clinical features, mechanisms, and management strategies. Biomedicines. 2025;13(12):3044.","journal-title":"Biomedicines"},{"issue":"5","key":"1570_CR178","first-page":"387","volume":"80","author":"AF Alexis","year":"2007","unstructured":"Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387\u201394.","journal-title":"Cutis"},{"issue":"6","key":"1570_CR179","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1684\/ejd.2016.2844","volume":"26","author":"F Ricci","year":"2016","unstructured":"Ricci F, De Simone C, Del Regno L, et al. Drug-induced hair colour changes. Eur J Dermatol. 2016;26(6):531\u20136.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"1570_CR180","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jocd.12686","volume":"17","author":"A Yadav","year":"2018","unstructured":"Yadav A, Garg T, Mandal AK, et al. Quality of life in patients with acquired pigmentation: an observational study. J Cosmet Dermatol. 2018;17(6):1293\u20134.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"1570_CR181","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/jdv.70149","volume":"40","author":"D Fattore","year":"2026","unstructured":"Fattore D, Apalla Z, Freites-Martinez A, et al. Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement. J Eur Acad Dermatol Venereol. 2026;40(5):739\u201359.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1570_CR182","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1111\/jdv.20282","volume":"39","author":"D Fattore","year":"2025","unstructured":"Fattore D, Lauletta G, Apalla Z, et al. Dermatologic immune\u2010related adverse events: it is time for a game change! J Eur Acad Dermatol Venereol. 2025;39(3):e271\u20132.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01570-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:38Z","timestamp":1783821758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01570-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":182,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01570-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohammadsalman Parsapour, Navid Omidkhoda, Amir Hooshang Mohammadpour, and Omid Arasteh have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No new datasets were generated during this study. All data analyzed are derived from previously published studies cited in this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: OA, NO; methodology: AHM, NO, MSP; literature search: MSP; data curation: MSP, NO; visualization (tables and figures): MSP; writing (original draft): MSP; writing (review and editing): NO, AA, MSP, AHM; supervision: OA. All authors have read and approved the final version and declare their agreement to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}